E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Major Depressive Disorder |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10081270 |
E.1.2 | Term | Major depressive disorder |
E.1.2 | System Organ Class | 100000004873 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of trazodone once-a day monotherapy in improving depression symptoms in patients with breast cancer and co-morbid major depressive disorder after 8-week treatment period. |
|
E.2.2 | Secondary objectives of the trial |
To assess the patient’s evaluation of depressive symptoms, functional recovery including cognitive and behavioural responses, quality of life, the compliance of antidepressant treatment, and safety over the 12-weeks study period. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Female patients of any ethnic origin between 18 and 64 years of age (limits included). 2. Outpatients with non-metastatic breast cancer under endocrine therapy. The primary diagnosis of breast cancer must be confirmed by appropriate clinical and instrumental assessment. 3. Outpatients who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for MDD diagnosis, experiencing a current major depressive episode of at least moderate severity, defined by a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥20 at Baseline Visit. 4. Patients eligible to start treatment with trazodone once-a-day monotherapy at Baseline Visit. In case of switch from other antidepressant drug, the related tapering schedule should be completed at the time of study inclusion. 5. Women of childbearing potential and women with no menses for a period <12 months must have a negative pregnancy test at Baseline Visit and have to agree not to start a pregnancy from the signature of the informed consent up to the Final Visit, using an appropriate birth control method such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormonereleasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. The following definitions will be considered: - Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. 6. Patients legally capable of giving their written consent to participate in the study (including personal data processing) and willing to comply with all study procedures. |
|
E.4 | Principal exclusion criteria |
1.Patients who meet any of the contraindications to the administration of trazodone once-a-day according to the approved local SmPC. 2. Known hypersensitivity or allergy to the active ingredient and/or to any component of the study medication. 3. Patients with locally advance or metastatic breast cancer or receiving adjuvant chemotherapy. 4. Concomitant treatment with other antidepressant drugs (use is forbidden for the whole study duration) and/or proved resistance to the trazodone once a- day monotherapy. 5. Patients with previous or current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, severe personality disorder, mental retardation, organic mental disorders or mental disorders due to a general medical condition. 6. Patients with previous or current history of a clinically significant neurological disorder, or any neurodegenerative disease, or other relevant condition (e.g. heart disease) that, in the opinion of the Investigator, might compromise participation in the study. 7. Patients who are at risk of suicide defined by a score ≥4 in MADRS item #10 at Baseline Visit. 8. Women during pregnancy or lactation period. 9. Clinically significant abnormalities on physical examination, vital signs and/or laboratory values (as assessed per routine clinical practice) at Baseline Visit which, in the opinion of the Investigator, could interfere with the study procedures or endpoints evaluation. 10. Patients with known cardiovascular disease including those associated to the prolongation of the QT interval (e.g. QTcF value higher than 450 msec for male and QTcF value higher than 470 msec for female) 11. Suspicious or confirmed COVID-19 infection according to the patient’s symptoms at the time of Baseline Visit. 12. Inability to comply with the protocol requirements (i.e. uncooperative attitude, inability to return to study visits, unlikelihood of completing the clinical study). 13. Subject involved in the conduct of the study (e.g. Investigator or her deputy, first grade relatives, pharmacist, assistant or other personnel). 14. Participation to an interventional clinical trial within 3 months of Baseline Visit.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The mean change in Montgomery-Asberg Depression Rating Scale (MADRS) score from Baseline Visit to Visit 3. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
-mean changes in MADRS score from Baseline Visit to Visits 1, 2 and 4 -changes in the distribution of Clinical Global Impression (CGI) from Baseline Visit to Visits 1, 2, 3 and 4 -mean changes in Brief Symptom Inventory modified version (BSI-18 MOD) total score from Baseline Visit to Visits 1, 2, 3 and 4 -changes in the distribution of Insomnia Severity Index (ISI) from Baseline Visit to Visits 1, 2, 3 and 4 -mean changes in Biological Rhythms Interview for Assessment in Neuropsychiatry (BRIAN) total score from Baseline Visit to Visit 4 - mean changes in Mini-Mental Adjustment to Cancer Scale (Mini-MAC) total score from Baseline Visit to Visits 3 and 4 - changes in EuroQuality of Life 5 dimensions – 5 level (EQ-5D-5L) and mean changes in the Visual Analogue Scale (VAS) from Baseline Visit to Visits 3 and 4 comparison between MADRS, BSI-18 MOD, Mini-MAC and VAS of EQ-5D-5L at Baseline Visit, Visit 3 and Visit 4 -compliance to antidepressant treatment (calculated as number of trazodone once-a-day tablets taken by patient since Baseline Visit until the last day of medication) -changes in concomitant medications for treatment of depression over the 12-weeks study period - safety evaluation |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
-Visit 1,2 and 4 -Visit 1,2,3 and 4 -Visit 1,2,3 and 4 -Visit 1,2,3 and 4 -Visit 4 -Visit 3 and 4 -Visit 3 and 4 -Visit 3 and 4 -last day of medication -12 weeks -12 weeks
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |